Renaissance Technologies (RenTech)'s EW Position Overview
Renaissance Technologies (RenTech) (via Renaissance Technologies LLC) currently holds 29,000 shares of Edwards Lifesciences Corporation (EW) worth $2.32 M, representing 0.00% of the portfolio. First purchased in 2013-Q2, this long-term strategic position has been held for 44 quarters.
Based on 13F filings since 2013, Renaissance Technologies (RenTech) has maintained a long-term strategic position in EW, representing a significant commitment to this investment thesis. Largest addition occurred in Q3 2017, adding 4.04 M shares. Largest reduction occurred in Q4 2017, reducing 2.82 M shares.
Analysis based on 13F filings available since 2013 Q2
Renaissance Technologies (RenTech)'s Edwards Lifesciences Corporation (EW) Holding Value Over Time
Track share changes against reported price movement
Quarterly Edwards Lifesciences Corporation (EW) Trades by Renaissance Technologies (RenTech)
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | +29,000 | New Buy | 29,000 | $80.08 |
| Q3 2025 | -1.04 M | Sold Out | 0 | $0.00 |
| Q2 2025 | +33,786 | Add 3.36% | 1.04 M | $78.21 |
| Q1 2025 | +354,107 | Add 54.27% | 1.01 M | $72.48 |
| Q4 2024 | -569,207 | Reduce 46.59% | 652,493 | $74.03 |
| Q3 2024 | +1.22 M | New Buy | 1.22 M | $65.99 |
| Q4 2023 | -497,000 | Sold Out | 0 | $0.00 |
| Q3 2023 | +497,000 | New Buy | 497,000 | $69.28 |
| Q2 2023 | -452,204 | Sold Out | 0 | $0.00 |
| Q1 2023 | -784,696 | Reduce 63.44% | 452,204 | $0.08 |
| Q4 2022 | +1.04 M | Add 527.55% | 1.24 M | $0.07 |
| Q3 2022 | +197,100 | New Buy | 197,100 | $82.63 |
| Q1 2022 | -5,800 | Sold Out | 0 | $0.00 |
| Q4 2021 | -208,600 | Reduce 97.29% | 5,800 | $129.48 |
| Q3 2021 | +206,300 | Add 2546.91% | 214,400 | $113.21 |
| Q2 2021 | -299,900 | Reduce 97.37% | 8,100 | $103.58 |
| Q1 2021 | +308,000 | New Buy | 308,000 | $83.64 |
| Q4 2020 | -37,100 | Sold Out | 0 | $0.00 |
| Q3 2020 | -848,300 | Reduce 95.81% | 37,100 | $79.81 |
| Q2 2020 | -328,700 | Reduce 27.07% | 885,400 | $69.11 |
| Q1 2020 | +796,410 | Add 190.67% | 1.21 M | $62.87 |
| Q4 2019 | +417,690 | New Buy | 417,690 | $77.76 |
| Q3 2018 | -1.48 M | Sold Out | 0 | $0.00 |
| Q2 2018 | -1.54 M | Reduce 50.89% | 1.48 M | $48.52 |
| Q1 2018 | -760,641 | Reduce 20.12% | 3.02 M | $46.51 |
| Q4 2017 | -2.82 M | Reduce 42.73% | 3.78 M | $37.57 |
| Q3 2017 | +4.04 M | Add 158.03% | 6.6 M | $36.44 |
| Q2 2017 | -220,200 | Reduce 7.92% | 2.56 M | $39.41 |
| Q1 2017 | +183,300 | Add 7.06% | 2.78 M | $31.36 |
| Q4 2016 | -1.83 M | Reduce 41.40% | 2.6 M | $31.23 |
| Q3 2016 | -2.21 M | Reduce 33.31% | 4.43 M | $40.19 |
| Q2 2016 | +1.64 M | Add 32.90% | 6.64 M | $33.24 |
| Q1 2016 | +1.68 M | Add 50.74% | 5 M | $29.40 |
| Q4 2015 | +1.15 M | Add 52.93% | 3.32 M | $26.33 |
| Q3 2015 | +426,672 | Add 24.50% | 2.17 M | $23.70 |
| Q2 2015 | -2.27 M | Reduce 56.58% | 1.74 M | $23.74 |
| Q1 2015 | +1.1 M | Add 37.96% | 4.01 M | $23.74 |
| Q4 2014 | +2.78 M | Add 2218.18% | 2.91 M | $21.23 |
| Q3 2014 | +9,600 | Add 8.29% | 125,400 | $17.03 |
| Q2 2014 | +115,800 | New Buy | 115,800 | $14.31 |
| Q1 2014 | -1.13 M | Sold Out | 0 | $0.00 |
| Q4 2013 | -558,600 | Reduce 33.03% | 1.13 M | $10.96 |
| Q3 2013 | +219,600 | Add 14.92% | 1.69 M | $11.61 |
| Q2 2013 | +1.47 M | Add 0.00% | 1.47 M | $11.20 |
Renaissance Technologies (RenTech)'s Edwards Lifesciences Corporation Investment FAQs
Renaissance Technologies (RenTech) first purchased Edwards Lifesciences Corporation (EW) in Q2 2013, acquiring 1,471,800 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies (RenTech) has held Edwards Lifesciences Corporation (EW) for 44 quarters since Q2 2013.
Renaissance Technologies (RenTech)'s largest addition to Edwards Lifesciences Corporation (EW) was in Q3 2017, adding 6,602,217 shares worth $240.56 M.
According to the latest 13F filing for Q1 2026, Renaissance Technologies (RenTech)'s firm, Renaissance Technologies LLC, owns 29,000 shares of Edwards Lifesciences Corporation (EW), valued at approximately $2.32 M.
As of the Q1 2026 filing, Edwards Lifesciences Corporation (EW) represents approximately 0.00% of Renaissance Technologies (RenTech)'s publicly disclosed stock portfolio, making it one of their key holdings.
Renaissance Technologies (RenTech)'s peak holding in Edwards Lifesciences Corporation (EW) was 6,641,400 shares, as reported at the end of Q2 2016.